This is a routine weekly update on the ongoing buyback program. No new information on the pace or scope of the program. Monitor for any changes to the buyback authorization or completion announcement.
NVO drugs
NVO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 9 $41.38entry
- T+1 · 7d ago −1.64%α −1.28% · $40.70
- T+5 · 20h ago +0.53%α +2.22% · $41.60
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Novo Nordisk filed a routine 6-K updating its ongoing share repurchase program, reporting the repurchase of 890,000 B shares for approximately DKK 243.6 million between November 3-6, 2026. The filing contains no financial results or material corporate events.
Key Facts
- Novo Nordisk repurchased 890,000 B shares from November 3-6, 2026 at an average price of DKK 273.57 per share, totaling approximately DKK 243.6 million
- Total accumulated repurchases under the program initiated May 6, 2026: 27,845,000 B shares for DKK 8.008 billion
- Overall 12-month buyback program of up to DKK 15 billion began February 4, 2026; as of November 6, 2026, total repurchases were DKK 11.808 billion
- Company holds 56,644,876 B shares as treasury shares, representing 1.3% of total share capital of 4.465 billion shares
Financial Impact
Routine buyback update; total program size up to DKK 15 billion (~$2.1B at current rates), with DKK 11.8 billion already deployed
Risk Factors
- No material risks identified in this routine filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-007260 |
| Document: 0001171843-26-007260-index-headers.html | 0001171843-26-007260 |
| Document: 0001171843-26-007260-index.html | 0001171843-26-007260 |
| Document: 0001171843-26-007260.txt | 0001171843-26-007260 |
| Earnings Context (Synthetic; results releases only) | 0001171843-26-007260 |
Track record
43 reports on NVO
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +23.56% at T+60 after the Jul 28, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $41.89 Now $41.60 −0.69% settles Dec 15
- Nov 13, 20264d ago Court Ruling Neutral 3/10 Entry $42.01 Now $41.60 −0.98% settles Dec 15
- Nov 13, 20264d ago Court Ruling Neutral 1/10 Entry $42.01 Now $41.60 −0.98% settles Dec 15
- Nov 9, 20267d ago 6-K Neutral 2/10 Viewing Entry $41.38 Now $41.60 +0.53% settles Dec 8
- Nov 5, 202611d ago Institutional Cluster Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
- Nov 5, 202611d ago 6-K Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
- Nov 4, 202612d ago 6-K Bullish 6/10 Entry $42.18 Now $41.60 −1.38% settles Dec 3
- Nov 3, 202613d ago 6-K Neutral 2/10 Entry $40.19 Now $41.60 +3.51% settles Dec 2
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $39.13 Now $41.60 +6.31% settles Nov 23
- Oct 26, 202622d ago Court Ruling Neutral 4/10 Entry $38.67 Now $41.60 +7.58% settles Nov 24
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers